These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 14505666)

  • 21. Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.
    Brooks DA; Etgen GJ; Rito CJ; Shuker AJ; Dominianni SJ; Warshawsky AM; Ardecky R; Paterniti JR; Tyhonas J; Karanewsky DS; Kauffman RF; Broderick CL; Oldham BA; Montrose-Rafizadeh C; Winneroski LL; Faul MM; McCarthy JR
    J Med Chem; 2001 Jun; 44(13):2061-4. PubMed ID: 11405642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential.
    Dey D; Medicherla S; Neogi P; Gowri M; Cheng J; Gross C; Sharma SD; Reaven GM; Nag B
    Metabolism; 2003 Aug; 52(8):1012-8. PubMed ID: 12898466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and structure-activity relationship studies of cinnamic acid-based novel thiazolidinedione antihyperglycemic agents.
    Neogi P; Lakner FJ; Medicherla S; Cheng J; Dey D; Gowri M; Nag B; Sharma SD; Pickford LB; Gross C
    Bioorg Med Chem; 2003 Sep; 11(18):4059-67. PubMed ID: 12927868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenylacetic acid derivatives as hPPAR agonists.
    Santini C; Berger GD; Han W; Mosley R; MacNaul K; Berger J; Doebber T; Wu M; Moller DE; Tolman RL; Sahoo SP
    Bioorg Med Chem Lett; 2003 Apr; 13(7):1277-80. PubMed ID: 12657263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel oximes having 5-benzyl-2,4-thiazolidinedione as antihyperglycemic agents: synthesis and structure-activity relationship.
    Yanagisawa H; Takamura M; Yamada E; Fujita S; Fujiwara T; Yachi M; Isobe A; Hagisawa Y
    Bioorg Med Chem Lett; 2000 Feb; 10(4):373-5. PubMed ID: 10714503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subtype specific effects of peroxisome proliferator-activated receptor ligands on corepressor affinity.
    Stanley TB; Leesnitzer LM; Montana VG; Galardi CM; Lambert MH; Holt JA; Xu HE; Moore LB; Blanchard SG; Stimmel JB
    Biochemistry; 2003 Aug; 42(31):9278-87. PubMed ID: 12899614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: peroxisome proliferator-activated receptor γ selective agonists with protein-tyrosine phosphatase 1B inhibition.
    Otake K; Azukizawa S; Fukui M; Kunishiro K; Kamemoto H; Kanda M; Miike T; Kasai M; Shirahase H
    Bioorg Med Chem; 2012 Jan; 20(2):1060-75. PubMed ID: 22197396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
    Reddy KA; Lohray BB; Bhushan V; Bajji AC; Reddy KV; Reddy PR; Krishna TH; Rao IN; Jajoo HK; Rao NV; Chakrabarti R; Dileepkumar T; Rajagopalan R
    J Med Chem; 1999 Jun; 42(11):1927-40. PubMed ID: 10354401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes.
    Richter HG; Benson GM; Blum D; Chaput E; Feng S; Gardes C; Grether U; Hartman P; Kuhn B; Martin RE; Plancher JM; Rudolph MG; Schuler F; Taylor S; Bleicher KH
    Bioorg Med Chem Lett; 2011 Jan; 21(1):191-4. PubMed ID: 21134747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Revisiting glitazars: thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents.
    Raval P; Jain M; Goswami A; Basu S; Gite A; Godha A; Pingali H; Raval S; Giri S; Suthar D; Shah M; Patel P
    Bioorg Med Chem Lett; 2011 May; 21(10):3103-9. PubMed ID: 21450468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peroxisome proliferator activator receptor-gamma agonists and 15-deoxy-Delta(12,14)(12,14)-PGJ(2) induce apoptosis in normal and malignant B-lineage cells.
    Padilla J; Kaur K; Cao HJ; Smith TJ; Phipps RP
    J Immunol; 2000 Dec; 165(12):6941-8. PubMed ID: 11120820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice.
    Kuwabara K; Murakami K; Todo M; Aoki T; Asaki T; Murai M; Yano J
    J Pharmacol Exp Ther; 2004 Jun; 309(3):970-7. PubMed ID: 14982965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities.
    Doebber TW; Kelly LJ; Zhou G; Meurer R; Biswas C; Li Y; Wu MS; Ippolito MC; Chao YS; Wang PR; Wright SD; Moller DE; Berger JP
    Biochem Biophys Res Commun; 2004 May; 318(2):323-8. PubMed ID: 15120604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benzoxazinones as PPARgamma agonists. part 1: SAR of three aromatic regions.
    Rybczynski PJ; Zeck RE; Combs DW; Turchi I; Burris TP; Xu JZ; Yang M; Demarest KT
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2359-62. PubMed ID: 12824034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Study on 3D-QSAR of PPAR gamma agonists with thiazolidinedione and arylketo-acid moieties].
    Yi X; Guo ZR
    Yao Xue Xue Bao; 2001 Apr; 36(4):262-8. PubMed ID: 12580053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
    Etgen GJ; Oldham BA; Johnson WT; Broderick CL; Montrose CR; Brozinick JT; Misener EA; Bean JS; Bensch WR; Brooks DA; Shuker AJ; Rito CJ; McCarthy JR; Ardecky RJ; Tyhonas JS; Dana SL; Bilakovics JM; Paterniti JR; Ogilvie KM; Liu S; Kauffman RF
    Diabetes; 2002 Apr; 51(4):1083-7. PubMed ID: 11916929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological activity of a novel series of indole-derived PPARgamma agonists.
    Henke BR; Adkison KK; Blanchard SG; Leesnitzer LM; Mook RA; Plunket KD; Ray JA; Roberson C; Unwalla R; Willson TM
    Bioorg Med Chem Lett; 1999 Dec; 9(23):3329-34. PubMed ID: 10612594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.
    Adams AD; Hu Z; von Langen D; Dadiz A; Elbrecht A; MacNaul KL; Berger JP; Zhou G; Doebber TW; Meurer R; Forrest MJ; Moller DE; Jones AB
    Bioorg Med Chem Lett; 2003 Oct; 13(19):3185-90. PubMed ID: 12951090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel 2-aryl-naphtho[1,2-d]oxazole derivatives as potential PTP-1B inhibitors showing antihyperglycemic activities.
    Kumar A; Ahmad P; Maurya RA; Singh AB; Srivastava AK
    Eur J Med Chem; 2009 Jan; 44(1):109-16. PubMed ID: 18436346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-based design of potent retinoid X receptor alpha agonists.
    Haffner CD; Lenhard JM; Miller AB; McDougald DL; Dwornik K; Ittoop OR; Gampe RT; Xu HE; Blanchard S; Montana VG; Consler TG; Bledsoe RK; Ayscue A; Croom D
    J Med Chem; 2004 Apr; 47(8):2010-29. PubMed ID: 15056000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.